Cue Biopharma, Inc. (CUE) Key Statistics & Financial Ratios

Cue Biopharma, Inc. (CUE) — Price $34.17 HealthcareBiotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Cue Biopharma, Inc. (CUE). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic.

Stock Data

Price$34.17
Market Cap$90M
Enterprise Value$81.2M
Beta1.58
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-1.17
Price / Book86.85
P/S2.21
EV/EBITDA-0.85
EV/Sales2.16
EV/FCF-1.62
P/FCF-1.66
Earnings Yield-75.74%
FCF Yield-55.87%
Dividend Yield0.00%

Profitability

Gross Margin99.69%
EBIT Margin-260.55%
EBITDA Margin-254.67%
Operating Margin-261.97%
Net Margin-435.83%
Return on Equity-1032.19%
Return on Assets-534.43%
Return on Invested Capital-887.33%
Return on Capital Employed-1039.56%

Financial Health

Current Ratio1.25
Quick Ratio1.25
Cash Ratio0.82
Debt / Equity3.81
Debt / Assets28.68%
Net Debt / EBITDA0.09
Interest Coverage-730.70
Piotroski F-Score4
Altman Z-Score-11.88

Per-Share Data

Revenue per share5.94
Book Value per share0.36
Cash per share2.74
FCF per share-7.91
Tangible Book Value per share0.36
Dividend per share0.00

Analyst Consensus

Strong Buy0
Buy9
Hold0
Sell0
Strong Sell0
Total analysts9
Avg rating (1-5)1.00

Related companies: BRNS · COEP · EQ · IOBT · IPSC · MDCX · NRXP

Explore sector: Healthcare · Biotechnology

More sections of CUE: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks